Abstract library

4 results for "Afchain".
#501 FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About one Case
Introduction: The treatment for progressive metastatic well-differentiated pancreatic neuroendocrine tumors is based on adriamycin and streptozotocin chemotherapy, which achieves more than 60% tumor regression. However, severe adverse effects are common.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Doctor Leïla Bengrine-Lefevre
#1252 Radio-chemotherapy versus Surgery in Non-metastatic Ano-rectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues
Introduction: Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at diagnosis and treated with a platinum-based chemotherapy. No guidelines for localized tumors exist.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Bertrand Brieau
#2189 Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract
Introduction: Neuroendocrine carcinomas (NEC), of the digestive tract are rare and aggressive tumours. In localised disease, the treatment is surgery, followed by administration of adjuvant chemotherapy combining etoposide and platinum salts, justified by the high risk of secondary metastasis. No clinical study has proven the benefit of chemotherapy, and recommendations are based on expert consensus.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Anna Pellat
#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling
Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr Julien Hadoux